- Diabetes Mellitus, Type 2,
- Diabetic Nephropathies,
- Endothelin Receptor Antagonists,
- Glomerular Filtration Rate,
- Heart Failure,
- Sodium-Glucose Transporter 2 Inhibitors,
Risks of kidney failure and heart failure are markedly reduced by inhibition of the sodium glucose cotransporter 2 (SGLT2) in patients with diabetic kidney disease. In a post hoc analysis of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial, drop-in SGLT2 inhibitor usage during the atrasentan enrichment period led to greater reduction in albuminuria compared with atrasentan alone. These data support the hypothesis of greater longer-term kidney protection by combination SGLT2 inhibition and endothelin A receptor antagonism that could be tested in future clinical trials.
Available at: http://works.bepress.com/katherine-tuttle/366/